Objective:

To examine the association between the use of immunomodulators or biologics therapies and the risk of major adverse cardiovascular events (MACE) among older adults with inflammatory bowel disease (IBD).

Approach:

Key Findings:

• Add a statement linking findings to potential changes in clinical practice.

Interpretation:

Emphasize cautious application of findings in clinical settings.

Limitations:

• Include examples of potential confounding factors.

Conclusion:

Strengthen the call for urgent further research.

Source

Based on findings from:

Therapeutic Approaches for Inflammatory Bowel Disease: The Role of Immunomodulators, Biologics, and 5-Aminosalicylates in Cardiovascular Risk Management

Qi Jian, Naueen A. Chaudhry, Fanxing Du, Ellen Zimmermann, Tianze Jiao. Jama Network Open, 2026.

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2848255

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.